[Preclinical safety investigation of GB-115 dipeptide].
Eksp Klin Farmakol
; 73(6): 29-32, 2010 Jun.
Article
en Ru
| MEDLINE
| ID: mdl-20726348
ABSTRACT
Preclinical safety investigations of newly synthesized dipeptide compound GB-115 (amide N-phenylhexanoyl-glycyl-L-tryptophan), an antagonist of cholecystokinin receptors, were performed. No animals were lost after GB-115 acute oral administration at a maximum dose of 6000 mg/kg in mice and at 3500 mg/kg in rats. GB-115 administered per os during 6 months in rabbits and rats (both males and females) at the doses of 0.1 and 10 mg/kg induced no irreversible pathological changes in organs and systems studied. The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny. GB-115 at a dose of 10 mg/kg produced suppression of the inflammatory reaction to concanavalin A.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Receptores de Colecistoquinina
/
Dipéptidos
Límite:
Animals
Idioma:
Ru
Revista:
Eksp Klin Farmakol
Asunto de la revista:
FARMACOLOGIA
Año:
2010
Tipo del documento:
Article